Our mission is to advance the science of regenerative medicine using our innovative approach to stem cell therapeutics. In addition to making therapies available to a wider audience, we aim to further develop the extraordinary potential of our proprietary proteins in treating a broad array of illnesses.

Proteonomix’s research and development is focused on stem cell therapies for diabetes and cardiac injury. We have plans to lead the research community into the future with the introduction of a new platform for growing contaminant-free human stem cells that will serve as a catalyst for bringing feasible therapies to market.

Umbilical cord blood stem cells are already recognized as a viable treatment for more than 80 diseases, a number that will continue to grow. With this in mind, we are preparing to establish a cord blood bank that employs proprietary technology that will lead to a significant increase the donor-recipient match rate. We will also be launching a genetic diversity program to increase participation of minority groups that are currently under-represented in the pool of available cord blood stem cell units.

Headquartered in New York City, Proteonomix Holding, Inc. is working with leading institutions and scientists around the world.

02.10.09: Proteonomix, Inc. (PROT) Announces Definitive Agreement for Sale of Its Stem Cell Derived Cosmeceutical Products With Two Companies Headquartered in China

01.15.09: International Business Times announces Proteonomix, Inc.(PROT) is "One to Watch"

01.05.09:Proteonomix, Inc.(PROT) announces the appointment of Steven Byle to its Board of Directors effective January 15, 2009.

12.15.08: Proteonomix, Inc. Announces the Publication of Research on Use of Umbilical Cord Blood in Growing Undifferentiated Embryonic Stem Cells

12.08.08:Proteonomix, Inc. Announces That Its Subsidiary, Proteoderm, Inc., Has Entered Into a Letter of Intent With Sinoquest Investment Limited for the Licensing, Purchase and Distribution of Proteoderm's Co.